1. Volume 15, Issue 1, Pages 114-122 (January 2014)
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial 
Prof Peter Barrett-Lee, MD, Angela Casbard, MSc, Jacinta Abraham, FRCR, Prof Kerenza Hood, PhD, Prof Robert Coleman, MD, Peter Simmonds, FRACP, Hayley Timmins, BSc, Duncan Wheatley, FRCR, Robert Grieve, FRCR, Gareth Griffiths, PhD, Nick Murray, DPhil 
The Lancet Oncology 
Volume 15, Issue 1, Pages (January 2014)
DOI: /S (13)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
ITT=intention to treat. PP=per protocol. *Not all patients gave a reason and more than one reason could be given.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2
Risk difference of patients experiencing toxic effects (ibandronic acid–zoledronic acid)
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3
Pain severity (A) and use of analgesics (B) during the study period
Mean pain severity scores measured using the Brief Pain Inventory (BPI). Opioid use represents the percentage of patients reporting use of opioid and non-opioid analgesics at each visit, with 95% CIs.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

5. Figure 4
Cumulative incidence of skeletal-related events (A) and of first skeletal-related event (B) in the per-protocol population
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

6. Figure 5
Cumulative incidence of skeletal-related events in the intention-to-treat population
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

7. Figure 6 Overall survival in the intention-to-treat population
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions